BBC in Turkish
It has been said that an enhanced cancer drug may have an advanced disease in the UK.
Scientists say that the television television druggist (Tisitumab Vedotin), who has been diagnosed with 150 people who did not respond to the drug, incorporated the cancer cells and attacked the cells from inside.
The drug is effective for up to 6 months.
The drug, developed by experts from the Research Institute of Algeria in Central London and the Royal Marsden Cancer Hospital, was tested in six types of cancer in the number, including lung, cervical, bladder and somatic .
27% of cancer patients had advanced results in bladder.
According to a study published in the Lancet Oncology medical journal, 27% of bladder cancer patients responded to 26% of their patients; Cuban cancer patients respond well to treatment.
This rate was 13 per cent in a patient with esophageal cancer and small lung cancer cells. In seven per cent of patients with endometrial cancer, it was noted that the tinnitus rescued or stopped growing.
The research is now expanding to patients who are experiencing including pellen and pancreatic cancer.
Signals are also on the test to identify patients who can respond to this drug.
According to experts, the television is connected to the known receptor known as antiboder targets. There is a high level of engineer on the surface of many cancer cells. Then it is said that the drug will break down the cells; there.